摘要
目的探索可溶性T细胞免疫球蛋白黏蛋白结构域3(T cell immunoglobulin and mucin domain-3,Tim-3)在胰腺癌患者外周血中的表达及其与血清癌糖链抗原19-9(carbohydrate antigen 19-9,CA19-9)联合检测的诊断价值。方法纳入106名初诊的胰腺癌患者和65名年龄和性别相匹配的健康人作为研究对象。收集上述所有人的静脉血样,采用酶联免疫吸附试验(ELISA)定量检测Tim-3浓度。根据可溶性Tim-3和血清CA19-9的表达水平,建立受试者工作特征(receiver operator curve,ROC)曲线二元逻辑回归模型,比较血清CA19-9和可溶性Tim-3单独检测及两者联合检测的诊断效果。结果胰腺癌组的可溶性Tim-3的水平明显高于健康对照组(P<0.001)。III~IV期胰腺癌患者可溶性Tim-3的表达水平显著高于I~II期(P=0.003)。可溶性Tim-3诊断I~II期胰腺癌的AUC为0.856(95%CI:0.765~0.992P<0.001),血清CA19-9诊断I~II期胰腺癌的AUC为0.862(95%CI:0.772~0.926P<0.001),联合诊断的AUC为0.949(95%CI:0.880~0.985P<0.001);在健康人群与III~IV期胰腺癌患者中,可溶性Tim-3诊断III~IV期胰腺癌的AUC为0.927(95%CI:0.873~0.963P<0.001),血清CA19-9诊断III~IV期胰腺癌的AUC为0.933(95%CI:0.881~0.968P<0.001),联合诊断的AUC为0.989(95%CI:0.956~0.999,P<0.001)。结论可溶性Tim-3和血清CA19-9联合检测可提高胰腺癌患者的诊断率。
Objective To investigate the expression of soluble T cell immunoglobulin and mucin domain-3(Tim-3)in peripheral blood of patients with pancreatic cancer and its diagnostic value in combination with serum Carbohydrate antigen 19-9(CA19-9).Methods 106 newly diagnosed pancreatic cancer patients and 65 age and sex matched healthy individuals were enrolled.Tim-3 concentration was quantitatively determined by enzyme-linked immunosorbent assay(ELISA).According to the expression levels of soluble Tim-3 and serum CA19-9,a binary logistic regression model of receiver operating characteristic(ROC)curve was established to compare the diagnostic effects of serum CA19-9 and soluble Tim-3 alone or combined with the two tests.Results The levels of soluble Tim-3 in the pancreatic cancer group were significantly higher than those in the healthy control group(P<0.001).The expression level of soluble Tim-3 was significantly higher in patients with stage III-IV pancreatic cancer than in patients with stage I-II(P=0.003).The AUC of soluble Tim-3 diagnosis for stage I-II pancreatic cancer was 0.856(95%CI:0.765 to 0.992 P<0.001),Serum CA19-9 The AUC used for the stage I-II pancreatic cancer diagnosis was 0.862(95%CI:0.772 to 0.926 P<0.001),The AUC for the combined diagnosis was 0.949(95%CI:0.880-0.985 P<0.001);In a healthy population and in patients with stage III-IV pancreatic cancer,the AUC of soluble T I I-IV pancreatic cancer in stage III was 0.927(95%CI:0.873 to 0.963 P<0.001),the AUC of serum CA19-9 used for the diagnosis of stage III-IV pancreatic cancer was 0.933(95%CI:0.881 to 0.968 P<0.001),the AUC for the combined diagnosis was 0.989(95%CI:0.956 to 0.999 P<0.001).Conclusions The combination of soluble Tim-3 and serum CA19-9 can improve the diagnostic rate of pancreatic cancer patients.
作者
汪可
刘丽娟
崔现平
姜文营
于长涛
史金鑫
Wang Ke;Liu Lijuan;Cui Xianping;Jiang Wenying;Yu Changtao;Shi Jinxin(Department of General Surgery,Huamei Hospital,The Second People’s Hospital of Liaocheng,Liaocheng 252600,China;Department of Intensive Care Medicine,Huamei Hospital,the Second People’s Hospital of Liaocheng,Liaocheng 252600,China;Department of Hepatobiliary Surgery,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Liaocheng 252600,China)
出处
《中华内分泌外科杂志》
CAS
2023年第3期278-281,共4页
Chinese Journal of Endocrine Surgery
基金
山东省中医药科技项目(2021M030)。
